Targeting respiratory microbiomes in COPD and bronchiectasis.

Expert review of respiratory medicine Pub Date : 2024-03-01 Epub Date: 2024-06-12 DOI:10.1080/17476348.2024.2355155
Micheál Mac Aogáin, Pei Yee Tiew, Tavleen Kaur Jaggi, Jayanth Kumar Narayana, Shivani Singh, Philip M Hansbro, Leopoldo N Segal, Sanjay H Chotirmall
{"title":"Targeting respiratory microbiomes in COPD and bronchiectasis.","authors":"Micheál Mac Aogáin, Pei Yee Tiew, Tavleen Kaur Jaggi, Jayanth Kumar Narayana, Shivani Singh, Philip M Hansbro, Leopoldo N Segal, Sanjay H Chotirmall","doi":"10.1080/17476348.2024.2355155","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This review summarizes our current understanding of the respiratory microbiome in COPD and Bronchiectasis. We explore the interplay between microbial communities, host immune responses, disease pathology, and treatment outcomes.</p><p><strong>Areas covered: </strong>We detail the dynamics of the airway microbiome, its influence on chronic respiratory diseases, and analytical challenges. Relevant articles from PubMed and Medline (January 2010-March 2024) were retrieved and summarized. We examine clinical correlations of the microbiome in COPD and bronchiectasis, assessing how current therapies impact upon it. The potential of emerging immunotherapies, antiinflammatories and antimicrobial strategies is discussed, with focus on the pivotal role of commensal taxa in maintaining respiratory health and the promising avenue of microbiome remodeling for disease management.</p><p><strong>Expert opinion: </strong>Given the heterogeneity in microbiome composition and its pivotal role in disease development and progression, a shift toward microbiome-directed therapeutics is appealing. This transition, from traditional 'pathogencentric' diagnostic and treatment modalities to those acknowledging the microbiome, can be enabled by evolving crossdisciplinary platforms which have the potential to accelerate microbiome-based interventions into routine clinical practice. Bridging the gap between comprehensive microbiome analysis and clinical application, however, remains challenging, necessitating continued innovation in research, diagnostics, trials, and therapeutic development pipelines.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2024.2355155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: This review summarizes our current understanding of the respiratory microbiome in COPD and Bronchiectasis. We explore the interplay between microbial communities, host immune responses, disease pathology, and treatment outcomes.

Areas covered: We detail the dynamics of the airway microbiome, its influence on chronic respiratory diseases, and analytical challenges. Relevant articles from PubMed and Medline (January 2010-March 2024) were retrieved and summarized. We examine clinical correlations of the microbiome in COPD and bronchiectasis, assessing how current therapies impact upon it. The potential of emerging immunotherapies, antiinflammatories and antimicrobial strategies is discussed, with focus on the pivotal role of commensal taxa in maintaining respiratory health and the promising avenue of microbiome remodeling for disease management.

Expert opinion: Given the heterogeneity in microbiome composition and its pivotal role in disease development and progression, a shift toward microbiome-directed therapeutics is appealing. This transition, from traditional 'pathogencentric' diagnostic and treatment modalities to those acknowledging the microbiome, can be enabled by evolving crossdisciplinary platforms which have the potential to accelerate microbiome-based interventions into routine clinical practice. Bridging the gap between comprehensive microbiome analysis and clinical application, however, remains challenging, necessitating continued innovation in research, diagnostics, trials, and therapeutic development pipelines.

针对慢性阻塞性肺病和支气管扩张症的呼吸道微生物组。
导言:这篇综述总结了我们目前对慢性阻塞性肺病和支气管扩张症中呼吸道微生物组的了解。我们探讨了微生物群落、宿主免疫反应、疾病病理和治疗效果之间的相互作用:我们详细介绍了气道微生物组的动态、其在慢性呼吸系统疾病中的影响以及分析方面的挑战。我们检索并总结了 2010 年 1 月至 2024 年 3 月期间在 PubMed 和 Medline 上搜索到的相关文章。综述探讨了慢性阻塞性肺病和支气管扩张症中微生物组的临床相关性,评估了当前疗法对微生物组的影响。文章讨论了新兴免疫疗法、抗炎药物和抗菌策略的潜力,重点关注共生类群在维持呼吸系统健康中的关键作用,以及微生物组重塑在疾病管理中的前景:鉴于微生物组组成的异质性及其在疾病发生和发展中的关键作用,向微生物组导向疗法的转变很有吸引力。从传统的 "以病原体为中心 "的诊断和治疗方式到承认微生物组的诊断和治疗方式的转变,可以通过不断发展的跨学科平台来实现,这些平台有可能加速基于微生物组的干预措施进入常规临床实践。然而,弥合微生物组综合分析与临床应用之间的差距仍具有挑战性,需要在研究、诊断、试验和治疗开发管道方面不断创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信